The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Mursla Bio EvoLiver test, a non-invasive blood test for early-stage liver cancer detection. This milestone recognizes its potential to transform hepatocellular carcinoma (HCC) screening.
What Is the Mursla Bio EvoLiver Test?
Developed by UK-based Mursla Bio, the EvoLiver test is a liquid biopsy that analyzes extracellular vesicles (EVs) from a blood sample. Using advanced bioinformatics, EvoLiver detects liver cancer molecular signals earlier than standard diagnostic tools.
Unlike current tools such as ultrasound and alpha-fetoprotein (AFP) testing—which have limited sensitivity and specificity—EvoLiver has demonstrated 86% sensitivity and 88% specificity for early-stage HCC detection, according to The Lifesciences Magazine.
FDA Breakthrough Status for EvoLiver: Why It Matters
The FDA’s Breakthrough Device Program supports the development of technologies that offer significant advantages for life-threatening diseases. As Business Wire reports, this designation accelerates regulatory review and highlights EvoLiver’s clinical promise.
How the Mursla Bio EvoLiver Test Improves Liver Cancer Detection
Early diagnosis of hepatocellular carcinoma is crucial. Current surveillance tools often miss tumors at early stages. According to Medical Device Network, the EvoLiver test enables earlier, more accurate detection through a simple blood draw, increasing the likelihood of timely intervention.
Industry and Clinical Perspectives on EvoLiver’s Potential
As News-Medical.net notes, the EvoLiver test is receiving praise for its innovation and accessibility. Mursla Bio plans further clinical trials and commercial partnerships to bring EvoLiver to more providers.
Additionally, BioSpace confirms that additional studies are underway to validate the test in broader populations and support FDA approval for clinical use.
Conclusion: A Promising Future for Liver Cancer Diagnosis
The FDA’s Breakthrough Device Designation for the Mursla Bio EvoLiver test signals a major advancement in liver cancer diagnostics. With impressive accuracy and a non-invasive design, EvoLiver could become a critical tool for earlier detection and improved survival.
For more details, visit Business Wire, The Lifesciences Magazine, and Medical Device Network.
Medical Disclaimer: This content is for informational purposes only. It is not a substitute for medical advice, diagnosis, or treatment.
Explore More :
https://innovatemed.org
